Table 1

Baseline characteristics of the sample population

Adults
(≥16 years) n=3861
Children
(<16 years) n=527
Elderly subgroup*
(≥65 years) n=876
Age at diagnosis (years), mean (SD)45.9 (20.4)8.5 (4.0)74.7 (7.0)
Female, n (%)1845 (47.8)244 (46.3)372 (42.5)
Number diagnosed
 Era 11276 (33.0)133 (25.2)260 (29.7)
 Era 21452 (37.6)248 (47.1)322 (36.8)
 Era 31133 (29.3)146 (27.7)294 (33.6)
Germaine-Smith epilepsy-specific comorbidity index, mean (SD)0.8 (1.9)0.3 (1.0)2.1 (2.5)
 Era 10.6 (1.5)0.3 (1.0)1.4 (2.3)
 Era 20.8 (1.8)0.2 (0.7)2.0 (2.3)
 Era 31.1 (2.4)0.4 (1.2)2.7 (2.9)
Epilepsy type
 Generalised, n (%)324 (8.4)72 (13.7)65 (7.4)
  Era 1, n (% of era)91 (7.1)15 (11.3)15 (5.8)
  Era 2, n (% of era)119 (8.2)44 (17.7)22 (6.8)
  Era 3, n (% of era)114 (10.1)13 (8.9)28 (9.5)
 Focal (partial onset), n (%)475 (12.3)76 (14.4)114 (13.0)
  Era 1, n (% of era)162 (12.7)15 (11.3)46 (17.7)
  Era 2, n (% of era)153 (10.5)31 (12.5)29 (9.0)
  Era 3, n (% of era)160 (14.1)30 (20.5)39 (13.3)
 Unspecified3062 (79.3)379 (71.9)697 (79.6)
  Era 1, n (% of era)1023 (80.2)103 (77.4)199 (76.5)
  Era 2, n (% of era)1180 (81.3)173 (69.8)271 (84.2)
  Era 3, n (% of era)859 (75.8)103 (70.5)227 (77.2)
At least one AED treatment, n (%)3313 (85.8)417 (79.1)783 (89.4)
Total follow-up (patient-years)†16 483.922363.943257.28
Mean follow-up (years)4.34.53.7
 Era 16.77.36.0
 Era 24.14.63.7
 Era 31.71.81.7
  • Era 1: 1 April 2003 to 31 August 2007 (first NICE guidance); era 2: 1 September 2007 to 31 December 2011 (SANAD); era 3: 1 January 2012 to 31 May 2016 (second NICE guidance).

  • *Elderly patients are a subset of the adult patient population.

  • †Total follow-up, patient-years: calculated by adding the follow-up time for all patients.

  • AED, antiepileptic drug; NICE, National Institute for Health and Care Excellence; SANAD, Standard and New Antiepileptic Drugs.